AADI Logo

Aadi Bioscience, Inc. (AADI) 

NASDAQ
Market Cap
$55.7M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
400 of 775
Rank in Industry
206 of 432

Largest Insider Buys in Sector

AADI Stock Price History Chart

AADI Stock Performance

About Aadi Bioscience, Inc.

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Insider Activity of Aadi Bioscience, Inc.

Over the last 12 months, insiders at Aadi Bioscience, Inc. have bought $0 and sold $897,175 worth of Aadi Bioscience, Inc. stock.

On average, over the past 5 years, insiders at Aadi Bioscience, Inc. have bought $23.4M and sold $767,930 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,529,402 shares for transaction amount of $20M was made by Dalal Anupam (director) on 2021‑08‑26.

List of Insider Buy and Sell Transactions, Aadi Bioscience, Inc.

2024-10-03SaleCHIEF EXECUTIVE OFFICER
9,689
0.04%
$1.94$18,797+9.38%
2024-09-03SaleEXECUTIVE CHAIRMAN
40,000
0.1595%
$1.71$68,316+12.64%
2024-08-05SaleEXECUTIVE CHAIRMAN
5,652
0.0224%
$1.34$7,595+39.49%
2024-08-02SaleEXECUTIVE CHAIRMAN
18,933
0.0777%
$1.41$26,705+37.14%
2024-08-01SaleEXECUTIVE CHAIRMAN
15,415
0.0618%
$1.50$23,055+25.99%
2024-07-02SaleEXECUTIVE CHAIRMAN
8,652
0.0296%
$1.34$11,6120.00%
2024-07-01SaleEXECUTIVE CHAIRMAN
31,348
0.1161%
$1.45$45,6050.00%
2024-06-04SaleEXECUTIVE CHAIRMAN
20,225
0.0827%
$1.77$35,746+0.85%
2024-06-03SaleEXECUTIVE CHAIRMAN
19,775
0.0805%
$1.81$35,765-2.21%
2024-05-01SaleEXECUTIVE CHAIRMAN
40,000
0.162%
$1.93$77,184-6.70%
2024-04-02SaleEXECUTIVE CHAIRMAN
22,228
0.0925%
$2.23$49,513-15.83%
2024-04-01SaleEXECUTIVE CHAIRMAN
17,772
0.0725%
$2.31$41,101-20.35%
2024-03-04SaleEXECUTIVE CHAIRMAN
14,964
0.0532%
$2.10$31,415-23.67%
2024-03-01SaleEXECUTIVE CHAIRMAN
27,036
0.113%
$1.97$53,226-3.11%
2024-02-01SaleExecutive Chairman
42,000
0.1683%
$1.74$73,269+6.82%
2024-01-02SaleExecutive Chairman
42,000
0.1709%
$2.06$86,549-9.95%
2023-12-06SaleExecutive Chairman
7,037
0.0294%
$4.82$33,914-60.00%
2023-12-05SaleExecutive Chairman
15,740
0.0662%
$5.02$78,941-61.48%
2023-12-04SaleExecutive Chairman
10,876
0.0447%
$5.15$55,986-63.21%
2023-12-01SaleExecutive Chairman
8,347
0.035%
$5.14$42,881-62.22%

Insider Historical Profitability

<0.0001%
Satter Muneer A
5621835
22.809%
$2.26330
Khuong Chau Quang
5193946
21.073%
$2.2620
Novartis Bioventures Ltd10 percent owner
4049804
16.431%
$2.26121
WEISS PAUL Mdirector
1576167
6.3949%
$2.2610
Dalal Anupamdirector
1529402
6.2051%
$2.2610<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Avoro Capital Advisors Llc$6.67M11.612.85M0%+$00.08
ACUTA CAPITAL PARTNERS LLC$4.33M7.531.85M0%+$02.81
Alerce Investment Management L P$3.82M6.641.63M0%+$00.05
BlackRock$2.44M4.241.04M-3.76%-$95,062.42<0.0001
The Vanguard Group$2M3.49856,836-0.33%-$6,694.74<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.